SARS-CoV-2 Archives - Page 2 of 3

Current treatment in COVID-19 disease: a rapid review

Miguel Rodriguez-Guerra, Preeti Jadhav, Timothy J Vittorio

Article Type

Review

Published

29 Jan 2021

This review aims to assess the efficacy and safety of available therapies for COVID-19 in light of current evidence. These treatment options are compared based on their impact on symptom management, inpatient length of stay, and overall morbidity and mortality.

Coronavirus disease 2019 (COVID-19): latest developments in potential treatments

Kam Lun Hon MBBS, MD, Karen Ka Yan Leung MBBS, MRCPCH, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP, Su Yun Qian MD, Vivian PY Chan MPharm, MSc (Clin Pharm), BPharm, BCPPS, BCNSP, Patrick Ip MBBS, FRCPCH (Hon), FRCPCH, Ian CK Wong BPharm (Hons), MSc, PhD, FRCPCH (Hon)

Article Type

Review

Published

29 Jun 2020

This overview aims to review the current developments in preventive treatments and therapies for COVID-19.

Can vitamins and/or supplements provide hope against coronavirus?

Sarah M Michienzi PharmD, Melissa E Badowski PharmD

Article Type

Review

Published

22 Jun 2020

The goal of this narrative review is to evaluate current and ongoing clinical trials of vitamins and supplements, alone or in combination with each other or other therapies, for the treatment of COVID-19.

Neurological features of COVID-19 and their treatment: a review

Daniele Orsucci MD, Elena Caldarazzo Ienco MD, Gianpaolo Nocita MD, Alessandro Napolitano MD, Marco Vista MD

Article Type

Review

Published

11 Jun 2020

This review aims to summarize early findings on
the neurological features of COVID-19 and their treatment
approaches.

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Matteo Bassetti MD, PhD, Paolo Pelosi MD, FERS, Chiara Robba MD, PhD, Antonio Vena MD, PhD, Daniele Roberto Giacobbe MD

Article Type

Editorial

Published

26 May 2020

Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.